The generalized bone phenotype in children with neurofibromatosis 1: A sibling matched case-control study

American Journal of Medical Genetics, Part A

Volumn 161, Issue 7, 2013, Pages 1654-1661

  Armstrong, Linlea ^a   Jett, Kimberly ^a   Birch, Patricia ^a   Kendler, David L ^a   Mckay, Heather ^a,b   Tsang, Erica ^a   Stevenson, David A ^c   Hanley, David A ^d   Egeli, Deetria ^f   Burrows, Melonie ^f   Friedman, J M ^a,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f NONE

Author keywords

Bone mineral; Bone strength; Bone structure; Calcium; Children; Neurofibromatosis 1; Osteopenia; Osteoporosis; Ras pathway

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; NEUROFIBROMIN; PARATHYROID HORMONE;

ADOLESCENT; AGE; ARTICLE; BODY DENSITY; BODY HEIGHT; BODY WEIGHT; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM HOMEOSTASIS; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FEMUR; GEOMETRY; HEAD; HIP; HUMAN; LUMBAR SPINE; MALE; MORPHOLOGY; NEUROFIBROMATOSIS; PARATHYROID HORMONE BLOOD LEVEL; PHENOTYPE; PRIORITY JOURNAL; SEX; SIBLING; STRESS; TIBIA; TRABECULAR BONE; VITAMIN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIUM; CASE-CONTROL STUDIES; CHILD; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MALE; NEUROFIBROMATOSIS 1; PHENOTYPE; REFERENCE VALUES; REGRESSION ANALYSIS; SIBLINGS; TOMOGRAPHY, X-RAY COMPUTED; VITAMIN D; YOUNG ADULT;

ANIMALIA;

EID: 84879460689     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36001     Document Type: Article

References (34)

1. Anonymous. 1988. National Institutes of Health Consensus Development Conference Statement: Neurofibromatosis. Neurofibromatosis 1:172-178.
2. Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, Blazo M, Tran A, Carter S, Lewis RA, Plon SE, Phillips WA, O'brian Smith E, Ellis KJ, Lee B. 2008. Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab 94:105-111.
3. Duke PM, Litt IF, Gross RT. 1980. Adolescents' self-assessment of sexual maturation. Pediatrics 66:918-920.
4. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG. 2007. Decreased bone mineral density in neurofibromatosis type 1: Results from a pediatric cohort. J Pediatr Orthop 27:472-475.
5. Duman O, Ozdem S, Turkkahraman D, Olgac ND, Gungor F, Haspolat S. 2008. Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1. Brain Dev 30:584-588.
6. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF, Karsenty G. 2006. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4:441-451.
7. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
8. Illés T, Hlalmai V, de Jonge T, Dubousset J. 2001. Decreased bone mineral density in neurofibromatosis-1 cases with spinal deformities. Osteoporosis Int 12:823-827.
9. Institute of Medicine, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. 1997. Vitamin D. In: Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington D.C.: National Academy Press. pp 250-287.
10. Kontulainen SA, Macdonald HM, Khan KM, McKay HA. 2005. Examining bone surfaces across puberty: A 20-month pQCT trial. J Bone Miner Res 20:1202-1207.
11. Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS. 1999. The Canadian Multicentre Osteoporosis Study (CaMos): Background, rationale, methods. Can J Aging 18:376-387.
12. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2002. 2000 CDC Growth Charts for the United States: Methods and development. Vital Health Stat 11:1-190.
13. Kuorilehto T, Pöyhönen M, Bloigu R, Heikkinen J, Väänänen K, Peltonen J. 2005. Decreased bone mineral density and content in neurofibromatosis type 1: Lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928-936.
14. Lammert M, Kappler M, Mautner VF, Lammert K, Storkel S, Friedman JM, Atkins D. 2005. Decreased bone mineral density in cases with neurofibromatosis 1. Osteoporos Int 16:1161-1166.
15. Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D, Schooler T, Mautner VF. 2006. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet 43:810-813.
16. Li H, Liu Y, Zhang Q, Jing Y, Chen S, Song Z, Yan J, Li Y, Wu X, Zhang X, Zhang Y, Case J, Yu M, Ingram DA, Yang FC. 2009. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr Res 65:613-618.
17. Macdonald HM, Kontulainen SA, Mackelvie-O'Brien KJ, Petit MA, Janssen P, Khan KM, McKay HA. 2005. Maturity- and sex-related changes in tibial bone geometry, strength and bone-muscle strength indices during growth: A 20-month pQCT study. Bone 36:1003-1011.
18. Macdonald HM, Kontulainen SA, Khan KM, McKay HA. 2007. Is a school-based physical activity intervention effective for increasing tibial bone strength in boys and girls? J Bone Miner Res 22:434-446.
19. MacKelvie KJ, Khan KM, Petit MA, Janssen PA, McKay HA. 2003. A school-based exercise intervention elicits substantial bone health benefits: A 2-year randomized controlled trial in girls. Pediatrics 112:e447.
20. MacKelvie KJ, Petit MA, Khan KM, Beck TJ, McKay HA. 2004. Bone mass and structure are enhanced following a 2-year randomized controlled trial of exercise in prepubertal boys. Bone 34:755-764.
21. Petramala L, Giustini S, Zinnamosca L, Marinelli C, Colangelo L, Cilenti G, Formicuccia MC, D'Erasmo E, Calvieri S, Letizia C. 2012. Bone mineral metabolism in cases with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 304:325-331.
22. Prinzie P, Descheemaeker MJ, Vogels A, Cleymans T, Haselager GJ, Curfs LM, Hellinckx W, Onghena P, Legius E, van Lieshout CF, Fryns JP. 2003. Personality profiles of children and adolescents with neurofibromatosis type 1. Am J Med Genet Part A 118A:1-7.
23. Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, Schinke T, Mautner VF, Amling M. 2010. High bone turnover and accumulation of osteoid in cases with neurofibromatosis 1. Osteoporos Int 21:119-127.
24. Stevenson DA, Moyer-Mileur LJ, Carey JC, Quick JL, Hoff CJ, Viskochil DH. 2005. Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography. J Musculoskelet Neuronal Interact 5:145-149.
25. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH. 2007. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150:83-88.
26. Stevenson DA, Schwarz EL, Viskochil DH, Moyer-Mileur LJ, Murray M, Firth SD, D'Astous JL, Carey JC, Pasquali M. 2008. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 63:697-701.
27. Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S, Weng HY, Greene T, Reinker K, Swensen J, Chan RJ, Yang FC, Senbanjo L, Yang Z, Mao R, Pasquali M. 2011a. Bone resorption in syndromes of the Ras/MAPK pathway. Clin Genet 80:566-573.
28. Stevenson DA, Viskochil DH, Carey JC, Sheng X, Murray M, Moyer-Mileur L, Shelton J, Roberts WL, Bunker AM, Hanson H, Bauer S, D'Astous JL. 2011b. Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1. J Pediatr Endocrinol Metab 24:169-174.
29. Szudek J, Birch P, Friedman JM. 2000. Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet 37:933-938.
30. Tucker T, Schnabel C, Hartmann M, Friedrich R, Frieling I, Kruse HP, Mautner VF, Friedman JM. 2009. Bone health and fracture rate in individuals with NF1. J Med Genet 46:259-265.
31. Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, Cagozzi L, Garavelli L, Bernasconi S. 2003. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab 16:289-292.
32. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW. 2006. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891.
33. Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N. 2007. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr 96:1220-1222.
34. Yu X, Chen S, Potter OL, Murthy SM, Li J, Pulcini JM, Ohashi N, Winata T, Everett ET, Ingram D, Clapp WD, Hock JM. 2005. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36:793-802.